Use of alendronate in the treatment of vitamin D intoxication in infants

Turkish Journal of Pediatrics

Volumn 47, Issue 4, 2005, Pages 373-375

  Hatun, Şükrü ^a   Çizmecioǧlu, Filiz ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Bisphosphonates; Infancy; Vitamin D intoxication

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM ION; COLECALCIFEROL; DIURETIC AGENT; GLUCOCORTICOID; PHOSPHATE; VITAMIN D;

ANOREXIA; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CASE REPORT; DRUG USE; FEMALE; HUMAN; INFANCY; INFANT; KIDNEY CALCIFICATION; POLYDIPSIA; RICKETS; SIDE EFFECT; VITAMIN BLOOD LEVEL; VITAMIN D INTOXICATION; VOMITING;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CALCIUM; FEMALE; HUMANS; INFANT; VITAMIN D;

EID: 31344441134     PISSN: 00414301     EISSN: 00414301     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rizzoll R, Stoermann C, Ammann P, Bonjour JP. Hypercalcemia and hyperosteolysis in vitamin D intoxication: effects of clodronate therapy. Bone 1994; 15: 193-198.
2. Lee DC, Lee GY. The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication. J Toxicol Clin Toxicol 1998; 36: 719-721.
3. Selby PL, Davies M, Marks JS, Mawer EB. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. Clin Endocrinol 1995; 43: 531-536.
4. Bereket A, Erdogan T. Oral bisphosphonate therapy for vitamin D intoxication of the infant. Pediatrics 2003; 111: 899-901.
5. Glenville J, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998; 78: 1193-1231.
6. Raisz LG, Trummel CL, Hollick MF, DeLuca HF. 1,25-Dihydroxycholecalciferol: a potent stimulator of bone resorption in tissue culture. Science 1972; 175: 768-769.
7. Deftos JI, Roose BA. Medullary thyroid carcinoma and calcitonin gene expression. In: Peck WA (ed). Bone and Mineral Research, Annual 6. Amsterdam: Elsevier Science Publishers; 1989: 267.
8. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. New Engl J Med 1998; 339: 947-952.
9. Falk MJ, Heeger S, Lynch KA, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003; 111: 573-578.
10. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002; 110: 1293-1299.
11. Sellers E, Sharma A, Rodd C. The use of pamidronate in three children with renal disease. Pediatr Nephrol 1998; 12, 778-781.
12. Lteif AN, Zimmerman D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics 1998; 102: 990-993.
13. Kutluk MT, Hazar V, Akyuz C, et al. Childhood cancer and hypercalcemia: report of a case treated with pamidronate. J Pediatr 1997; 130: 828-831.
14. Shoemaker LR. Expanding role of bisphosphonate therapy in children. J Pediatr 1999; 134: 264-267.
15. Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003; 5: 65-74.
16. McCarthy EA, Raggio CL, Hossack MD, et al. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model. Pediatr Res 2002; 52: 660-667.